You are here

Resize Text
See all clinical trials

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

This is a randomized, placebo-controlled, double-blind, parallel group study to evaluate the safety and tolerability of GSK2881078, an SARM over 13 weeks of dosing in older male subjects and post-menopausal female subjects with COPD and muscle weakness. This study will also assess the effect of GSK2881078 on physical strength and function after 13 weeks of treatment. 

Clinical Trial Information

Protocol
TIRB#: 2510, WIRB#: 20172954
Phase
2
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Investigator
Gerard Criner, MD
Coordinator
Joe Lambert, Tiketta McIntyre

Visit clinicaltrials.gov for full clinical trial description.

Contact

For more information about this trial or to inquire about eligibility, email breathe@temple.edu

 

Full Title

A Randomized, Double-blind (Sponsor Unblind), Placebo-controlled, Multi-centred Phase IIa Study to Evaluate the Safety and Efficacy of 13 Weeks of Once Daily Oral Dosing of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Older Men and Post Menopausal Women With COPD and Muscle Weakness, Participating in Home Exercise